Now entering its third year, the COVID-19 virus is still one big health threat for the world's people. Today, we are yearning for the emergence of an effective drug that kills the COVID-19 virus in one fell swoop. The oral drug paxlovid and ensitrelvir could be game-changers.Huateng Pharma is a full-service Contract Development Manufacturing Organizations (CDMO) for pharmaceutical intermediates, including paxlovid and ensitrelvir intermediates, offering our customers innovative solutions to their bespoke projects, from the early clinical phase through to the commercial stage.
COVID-19 Drug Intermediates
Paxlovid IntermediatesPaxlovid is the first oral antiviral medicine for treating COVID-19, which contains two active substances, nirmatrelvir and ritonavir. We can provide the following paxlovid intermediates and CDMO services with sufficient capacity.
Ensitrelvir IntermediatesEnsitrelvir (code name S-217622) acts as an orally active 3C-like protease inhibitor for the treatment of COVID-19. It has demonstrated antiviral effectiveness against Delta variant and the Omicron variant. We can provide the following ensitrelvir intermediates and CDMO services with sufficient capacity.
Ensitrelvir, A Novel Antiviral Drug Against COVID-19